Derma Sciences Inc. (NASDAQ:DSCI) announced its quarterly earnings data on Thursday. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.01. The firm had revenue of $21.80 million for the quarter, compared to the consensus estimate of $23.90 million. Derma Sciences had a negative net margin of 21.19% and a negative return on equity of 11.74%.

Derma Sciences (NASDAQ:DSCI) opened at 4.35 on Thursday. The company’s 50-day moving average price is $4.65 and its 200 day moving average price is $4.37. The company’s market capitalization is $123.13 million. Derma Sciences has a 52-week low of $2.85 and a 52-week high of $5.86.

Earnings History for Derma Sciences (NASDAQ:DSCI)

Several brokerages have recently commented on DSCI. Zacks Investment Research upgraded Derma Sciences from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a research report on Wednesday, August 3rd. TheStreet upgraded Derma Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, August 9th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $7.25.

Institutional investors have recently made changes to their positions in the stock. UBS Asset Management Americas Inc. increased its position in shares of Derma Sciences by 18.6% in the third quarter. UBS Asset Management Americas Inc. now owns 236,950 shares of the company’s stock valued at $1,107,000 after buying an additional 37,134 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its position in shares of Derma Sciences by 2.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 153,052 shares of the company’s stock valued at $603,000 after buying an additional 3,613 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Derma Sciences by 1.1% in the second quarter. Vanguard Group Inc. now owns 802,878 shares of the company’s stock valued at $3,163,000 after buying an additional 8,376 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Derma Sciences by 15.6% in the second quarter. Dimensional Fund Advisors LP now owns 52,535 shares of the company’s stock valued at $207,000 after buying an additional 7,086 shares during the last quarter. Finally, Emerald Acquisition Ltd. purchased a new stake in Derma Sciences during the second quarter worth approximately $202,000. Institutional investors and hedge funds own 62.43% of the company’s stock.

Derma Sciences Company Profile

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

5 Day Chart for NASDAQ:DSCI

Receive News & Stock Ratings for Derma Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc. and related stocks with our FREE daily email newsletter.